Trump Announces 100% Tariffs On Imported Patented Pharmaceuticals

WASHINGTON, DC -The United States will impose tariffs of up to 100 per cent on imported patented pharmaceuticals, with President Donald Trump citing national security risks and heavy reliance on foreign supply chains.

In a proclamation April 2, Trump said pharmaceuticals and related ingredients “are being imported into the United States in such quantities and under such circumstances as to threaten to impair the national security of the United States.”

Under the order, most imported patented pharmaceuticals will face a 100 per cent ad valorem duty. Companies that commit to shifting production to the United States will be subject to a reduced 20 per cent tariff, which will rise to 100 per cent after four years.

The proclamation also outlines differentiated tariff rates for key trading partners. Imports from the European Union, Japan, South Korea and Switzerland will face lower tariffs of around 15 per cent, while certain specialized categories such as orphan drugs, nuclear medicines and gene therapies will remain exempt.

Generic drugs and biosimilars have been excluded from the tariff regime for now. “Generic pharmaceuticals and their associated ingredients shall not be subject to tariffs… at this time,” the proclamation said.

Officials said the policy is part of a broader effort to rebuild domestic pharmaceutical manufacturing and secure supply chains.

The decision is expected to have far-reaching implications for global pharmaceutical trade, especially for countries that serve as major suppliers of finished drugs and raw materials.

India and China are among the largest producers of generic medicines and active pharmaceutical ingredients globally, supplying a significant share of the US market. While generics are currently exempt, any future expansion of tariffs could have wider implications for global drug pricing and supply chains. (IANS)